Jade Biosciences, Inc. (JBIO)
| Market Cap | 958.41M +206.0% |
| Revenue (ttm) | n/a |
| Net Income | -124.44M |
| EPS | -2.34 |
| Shares Out | 63.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 596,541 |
| Open | 14.16 |
| Previous Close | 14.10 |
| Day's Range | 13.65 - 15.11 |
| 52-Week Range | 8.36 - 28.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 50.13 (+232.65%) |
| Est. Earnings | Nov 20, 2026 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $50.13, which is an increase of 232.65% from the latest price.
News
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026 JUNIPER Phase 2 Trial-in-Progress poster h...
Jade Biosciences management to meet with BTIG
Dinner Meeting with Management to be held in Denver on October 23 at 6 pm hosted by BTIG.
Jade Biosciences Transcript: Study update
JADE301, a novel anti-interferon beta antibody, showed superior preclinical potency and half-life versus dazukibart, supporting its potential as a best-in-class, subcutaneous therapy for dermatomyositis. Phase I is set for Q4 2026, with interim data expected in 2H 2027.
Jade Biosciences Press release: Study update
Jade Biosciences issued a press release on September 30, 2026, disclosing material business information to investors.
Jade Biosciences Slides: Study update
Jade Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Jade Biosciences announces preclinical data of JADE301
Jade Biosciences (JBIO) announced preclinical data characterizing JADE301. JADE301 is a fully human IgG1 monoclonal antibody with a YTE modification designed to selectively and potently neutralize IFN...
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β bin...
Jade Biosciences Slides: Company presentation
Jade Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Jade Biosciences Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Three advanced biologic programs are progressing in autoimmune diseases, with JADE101 leading in IgAN and aiming for deep IgA reduction and convenient dosing. Regulatory shifts enable faster, smaller pivotal trials, and the pipeline is positioned for strong differentiation and commercial potential.
Jade Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The pipeline features three autoimmune disease assets, led by JADE101 for IgA nephropathy, which demonstrated deep, sustained IgA reductions and is advancing rapidly toward pivotal trials. Strong financials support an accelerated timeline, with key data readouts for all programs expected by 2027.
Jade Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
The pipeline features three advanced autoimmune therapeutics, with JADE101 showing best-in-class potential for IgA nephropathy and rapid clinical progress. Strong financials and strategic trial designs support expansion into additional indications and efficient market entry.
Jade Biosciences Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing three main assets targeting autoimmune diseases, with JADE101 showing strong phase I results in IgA nephropathy and moving rapidly into phase II and III. Differentiation is based on potency, dosing convenience, and safety, with a robust financial position supporting progress through 2028.
Jade Biosciences price target raised to $48 from $25 at Clear Street
Clear Street raised the firm’s price target on Jade Biosciences (JBIO) to $48 from $25 and keeps a Buy rating on the shares. The firm believes Climb Bio’s (CLYM) CLYM116…
Jade Biosciences price target raised to $48 from $40 at Jefferies
Jefferies raised the firm’s price target on Jade Biosciences (JBIO) to $48 from $40 and keeps a Buy rating on the shares after the company reported Q2 results and gave…
Jade Biosciences price target raised to $47 from $45 at Wedbush
Wedbush raised the firm’s price target on Jade Biosciences (JBIO) to $47 from $45 and keeps an Outperform rating on the shares. Most important in the Q2 update, all development…
Jade Biosciences Slides: Company presentation
Jade Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Jade Biosciences reports Q2 EPS (76c) vs. (86c) last year
“This was an important period for Jade as we reported positive interim Phase 1 data for JADE101 that exceeded our expectations across biomarker activity and durability, with a favorable safety…
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical tr...
Jade Biosciences Earnings release: Q2 2026
Jade Biosciences released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Jade Biosciences Quarterly report: Q2 2026
Jade Biosciences has published its Q2 2026 quarterly earnings report on August 10, 2026.
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences initiated with a Buy at UBS
UBS initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $45 price target The firm believes the company’s lead program JADE101 could be a best-in-class drug in the…
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on deve...
Jade Biosciences Proxy statement: Proxy filing
Jade Biosciences filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.